Boston Scientific Corporation Heart Device Won’t Get Quick Review From FDA

March 26, 2010 |

1 min read

WSJ -- Regulators on Thursday said they won't speed up the review of manufacturing changes required for Boston Scientific Corp. to resume selling its implantable heart defibrillators.

Regulatory

MORE ON THIS TOPIC

Balance. A business man maintains a balance between life and work. vector

Regulatory

Acting CBER, CDER heads become permanent as FDA works to restore stability

September 9, 2026

·

2 min read

·

Tristan Manalac

Success to win in business competition, overcome obstacles or motivation to solve problem and lead company achievement concept, confident businessman leader jump high over 3 hurdles to be winner.

Approvals

AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer

September 8, 2026

·

2 min read

·

Tristan Manalac

Illustration of businessmen moving a mountain uphill. The men & mountain and background are on separate labeled layers.

Insights

Can Benelux turn scientific strength into larger biotech scale?

September 8, 2026

·

4 min read

·

Jennifer C. Smith-Parker

Document checking, agreement or contract validation, financial or budget analysis, search for document files concept, businessman manager holding big magnifying glass checking document paper.

FDA

Replimune’s melanoma drug would have been rejected again if not for senior CBER official

September 3, 2026

·

2 min read

·

Tristan Manalac